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Abstract 
Purpose of review 
Corneal transplantation is successful in the short term, but the long term prognosis has not 
improved over the past twenty years. Here, we review recent findings that may contribute to 
improved corneal allograft survival. 
Recent findings 
A better understanding of the molecular pathways affecting corneal graft survival has led to 
more targeted approaches to immune modulation. Co-stimulatory molecule blockade, 
inhibition of chemokine-chemokine receptor interactions, modulation of apoptotic pathways, 
and reduction of corneal neovascularization and lymphangiogenesis have been shown to 
prolong corneal graft survival in animal models. Conventional immunosuppressive drugs 
have been tested in new combinations and formulations with some success. Two randomised 
prospective clinical trials in clinical penetrating corneal transplantation have been reported, 
but there remains little evidence on the long-term outcomes of the newer lamellar corneal 
graft procedures. 
Summary 
New approaches to reducing the impact of rejection on corneal graft survival have focussed 
on topical rather than systemic therapies, and on component corneal transplantation. The most 
successful experimental strategies have been those in which more than one pathway has been 
targeted: it now seems likely that to improve clinical allograft survival, simultaneous 
modulation of multiple axes of the rejection process will be necessary. 
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Introduction 
Corneal transplantation is a commonly-performed procedure. Irreversible rejection is a major 
cause of clinical corneal allograft failure, accounting for at least 30% of all failures in registry 
series. At least seven major reviews discussing the mechanisms of corneal graft rejection have 
been published over the past year [1-7]. Unlike the case with solid organ transplantation, 
where graft failure may mean patient death, the loss of a corneal graft is not a life-threatening 
situation, so that aggressive therapy using drugs with potentially harmful systemic side-
effects is rarely justified. Topical therapy with glucocorticosteroid eye drops remains the 
mainstay of clinical therapy to prevent allograft rejection, with systemic immunosuppression 
being limited to high-risk cases that are often published as case reports. 
 
Recent findings in experimental models of corneal transplantation 
Appropriate animal models are essential for assessing the pathophysiology of corneal 
allograft rejection, whether it be in penetrating keratoplasty or in one of the newer lamellar 
techniques. 
 
New animal models 
A new model of penetrating keratoplasty that closely mimics the clinical and 
histopathological features seen in humans has been developed in the outbred miniature pig 
[8]. The model will be useful in the study of clinically-applicable regimens of 
immunosuppression, but corneal graft rejection has to be induced by inducing 
neovascularization of the host cornea prior to transplantation. New small-animal models have 
been developed in the mouse [9] and rabbit [10] to investigate immunological and functional 
features of corneal endothelial cell transplantation. When human corneal endothelial cells 
cultivated on the thermoresponsive biomaterial poly(N-isopropylacrylamide) were grafted as 
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monolayers to rabbit corneas denuded of endothelium, corneal clarity was gradually restored 
[10]. 
 
Chemokines, antigen presentation and neovascularization 
Corneal allograft rejection is associated with the expression of pro-inflammatory cytokines 
and chemokines. The upregulation of chemokine expression in corneas following exposure to 
lipopolysaccharide (bacterial endotoxin) or resulting from surgical trauma might be expected, 
but surprisingly, simple storage of murine corneas in corneal storage media such as Optisol or 
RPMI 1640 medium has also been shown to result in marked upregulation within the cornea 
of chemokines such as IP-10 (CXCL10), RANTES (CCL5) and MIP-2 (CXCL2) [11]. 
Human corneas are often stored in eye banks for several weeks prior to transplantation, but 
this practice may need to be reassessed. 
 
The presence of chemokine receptor CCR7-positive antigen presenting cells (APCs) in 
inflamed host corneas in proximity to CCL21+ and LYVE-1+ lymphatics and their 
subsequent migration to ipsilateral draining lymph nodes was recently demonstrated [12]. 
This migration was inhibited by subconjunctival injection of a blocking antibody to the CCR7 
ligand CCL21, suggesting that the CCR7-CCL21 interaction promotes access of antigen-
bearing APCs to the lymph node vasculature [12]. Such chemokine blockade might be a 
promising approach to preventing APC migration, because it appears relatively specific. 
 
The migration of APCs into or out of the cornea may depend to some extent on the 
development of new capillaries and lymphatics in the normally avascular cornea. Inhibition of 
corneal lymphangiogenesis by oral administration of two new vascular endothelial growth 
factor (VEGF) receptor tyrosine kinase inhibitors led to decreased recruitment of APCs into 
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the murine cornea, as well as improved corneal allograft survival in mice [13]. However, it 
seems likely that this systemic approach might be associated with significant side-effects in 
humans. Targeted gene therapy with a specific VEGF inhibitor might be more clinically 
applicable. Intraocular over-expression of the VEGF receptor sFLk-1 has been shown to 
inhibit corneal neovascularization caused by cautery in a rat model [14], but its effect on graft 
survival in corneal allograft transplantation remains to be demonstrated. 
 
Advances in drug treatments and synthetic delivery systems  
New strategies for immunosuppressive therapy in corneal transplantation include examination 
of different regimens of systemic administration of existing drugs, or alternatively topical 
therapy with established drugs, enhanced by improved formulations allowing continuous drug 
delivery. Systemic administration of the malononitrilamide immunosuppressant FK778 
resulted in a modest prolongation of rat corneal graft survival [15]. Similarly, systemic 
administration of the mineralocorticoid-receptor binding steroid spironolactone induced a 
moderate improvement of rat corneal allograft survival in association with upregulation of 
interleukin 10 (IL10) in the cornea, and decreased corneal neovascularization [16]. 
Cyclosporin A is used systemically for high-risk human corneal allografts with limited 
success, and concerns over its side-effects restrict wider use. Systemic cyclosporin is only 
moderately effective in preventing corneal rejection when given in conjunction with other 
immunosuppressive drugs in a high-risk pig model [8], but has shown some promise 
administered in a subconjunctival silicone implant [17]. Newer immunosuppressive agents 
have also been used topically in an attempt to delay or prevent corneal allograft rejection. 
Topical therapy with the calcineurin inhibitor pimecrolimus did not prolong corneal graft 
survival in a rat keratoplasty model [18], but in contrast, modest prolongation of rat corneal 
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allograft survival was seen with topical everolimus [19], which has been shown to possess 
good penetrative properties in organ-cultured pig corneas [20]. 
 
Gene therapy 
Gene therapy to prevent corneal graft rejection has remained a focus for many investigators. 
Non-viral methods of gene and siRNA transfer to the cornea utilising nanoparticles [21] or 
synthetic peptides [22] have also become more reliable. The development of cornea-specific 
promoters which can be used in association with non-viral delivery system via an eye drop is 
of interest for transgenes that may benefit from expression in corneal epithelium or stroma 
[23]. Localised corneal epithelial or stromal reporter gene expression was achieved using the 
cornea-specific promoters pK12 or pKera3.2, respectively, whilst the control cytomegalovirus 
(CMV)-promoter driven plasmid resulted in indiscriminate epithelial and stromal gene 
expression. The effectiveness and kinetics of lentiviral-mediated gene transfer to the cornea in 
a variety of species has been investigated, making comparison amongst species easier [24]. 
 
Co-stimulatory pathway blockade 
Broad and non-specific blockade of CD4 by the specific organic ligand J2, administered 
orally, abrogated T cell activation and improved corneal allograft survival in a high-risk 
murine model [25]. This report highlights the importance of systemic T cells in the corneal 
graft rejection process, but the approach would likely result in significant systemic 
immunosuppression and is thus unlikely to be applicable in clinical corneal transplantation. 
 
The more targeted inhibition of other potent co-stimulatory signals has shown promise in 
several experimental models. The B7 family comprises both activating and inhibitory 
molecules (Figure 1), and has drawn particular interest. Inhibition of different positive co-
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stimulatory signals has yielded variable results: neither local nor systemic expression of an 
ICOS-Ig by means of an adenoviral vector was effective in preventing rat corneal graft 
rejection [26], but systemic blockade of OX40 ligand significantly prolonged graft survival in 
the mouse [27]. Of particular interest was a report of a novel molecule that targets both co-
stimulatory and apoptosis-related pathways using a single molecule [28]. Incubation of donor 
corneas ex vivo prior to transplantation with a CTLA4-FasL molecule in a murine corneal 
graft model significantly improved graft survival, with the FasL component inducing 
apoptosis of infiltrating inflammatory cells. This approach also induced tolerance to 
subsequent donor-specific skin grafts, at least in those animals in which corneal grafts 
survived beyond 8 weeks. 
 
Programmed death ligands PD-L1 and PD-L2 are down-regulatory B7 superfamily members. 
PD-L1 was shown to be constitutively expressed in corneal tissue, and PD-L1 blockade with a 
specific antibody administered systemically enhanced corneal graft rejection [29]. Corneal 
transplantation in PD-L1 knock-out recipient mice resulted in accelerated rejection of wild-
type donor corneas; a similar effect was seen if PD-L1 knock-out donor corneas were 
transplanted to wild-type recipients. It is possible that localised PD-L1 over-expression may 
(in conjunction with other therapies) be useful in promoting corneal graft survival. 
 
Modulation of apoptotic pathways 
Rather than inducing apoptosis in infiltrating inflammatory cells, other investigators have 
attempted to prolong corneal graft survival by inhibiting apoptosis of corneal endothelial 
cells, since programmed cell death is a major mechanism of endothelial cell loss during 
rejection. Over-expression of bcl-xL following lentiviral viral gene transfer to donor corneal 
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endothelium was been shown to improve corneal graft survival significantly in a mouse 
model [30]. 
 
In another study, the inhibition of nitric oxide production in activated macrophages during 
murine corneal allograft rejection inhibited non-caspase-dependent apoptosis in endothelial 
cells, resulting in indefinite graft survival in some minor histocompatibility-disparate grafts 
but not in major histocompatibility complex-mismatched animals. [31]. This result was 
achieved by intraperitoneal or subconjunctival injection of N,N'-diacetyl-L-cystine 
dimethylester, an agent which reduces the intracellular glutathione content in APCs and 
dampens Th1 responses [31]. Inhibition of oxidative stress on endothelial cells by systemic 
injection of a specific inducible nitric oxide synthase enhanced corneal endothelial cell 
survival in transplanted rat corneas, but did not reduce the overall incidence of allograft 
rejection [32]. 
 
Cytokines and growth factors 
Neither systemic nor local adenoviral vector-mediated expression of viral IL-10 or 
mammalian p40 interleukin 12 resulted in improved corneal allograft survival in a rat model, 
despite altered cytokine expression profiles in the recipient corneas indicative of a partial Th2 
switch [33,34]. In contrast, adenoviral-vector-mediated over-expression of nerve growth 
factor (NGF) in rat corneas resulted in prolongation of allograft survival, and increased 
mRNA expression of the Th2 type cytokines interleukin 4 and IL-10 in the grafted corneas 
[35]. NGF has previously been shown to modulate the switch to a Th2 type immune response. 
Systemic NGF expression did not improve corneal allograft survival, but the combination of 
both systemic CTLA4-Ig and local NGF was effective [35]. 
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Recent findings in clinical corneal transplantation 
Corneal transplantation is in era of change. Despite a large number of reports of clinical 
corneal transplantation, few have provided high-level evidence. 
 
Evidence-based outcome studies 
Two randomized prospective clinical trials have been reported over the past year. Nguyen et 
al reported that long-term topical steroid improved graft survival following normal-risk 
penetrating keratoplasty [36]. Since the use of topical steroids is all but universal after corneal 
transplantation but the dose schedules vary from surgeon to surgeon, the new evidence for the 
long-term use of topical corticosteroids after corneal transplantation is valuable and overdue. 
Another study reported from the Cornea Donor Study Investigator Group set out the results 
from a prospective controlled clinical trial examining the effect of donor age on corneal graft 
survival [37]. They concluded that the five-year survival rate of grafts using donors under 65 
years was not different from the rate for donors over the age of 65 years. 
 
Ghosh and others reported a retrospective observational study which supported a role for 
long-term oral rather than topical acyclovir after corneal transplantation for herpetic keratitis 
[38]. Herpetic recurrences were less frequent and visual acuity after surgery was said to be 
better in those receiving oral acyclovir, but there was minimal difference in graft survival 
between the groups. 
 
Component corneal transplantation 
There is currently more pressure to change the surgical approach to corneal transplantation 
than at any time since the procedure was first used a hundred years ago. There has been a 
strong shift towards “component corneal transplantation” and away from full thickness 
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(penetrating) keratoplasty. The ambit claim is that replacement of only the abnormal layer of 
the cornea will reduce complications. The procedures fall into two groups, the first including 
procedures in which the corneal epithelium and stroma down to Descemet’s membrane is 
transplanted, and the second including procedures in which the host endothelium is replaced 
with donor endothelium, Descemet’s membrane and adjacent stroma. The procedures have 
been widely adopted, but whilst published reports are generally able to confirm the feasibility 
of the approaches, they fall short of providing comparative data.  
 
Deep anterior lamellar keratoplasty has been widely adopted as the surgical treatment for a 
number of conditions including keratoconus. Ardjomand et al reported a study comparing the 
visual outscore after lamellar and penetrating corneal transplantation for keratoconus [39]. In 
this cohort study, those with penetrating grafts achieved better visual acuity. A case series 
described by Noble et al reported post-operative outcomes that were comparable to those 
reported for penetrating keratoplasty in the past – but no better [40]. The follow-up was short, 
6 to 24 months. The status of the procedure as an alternative to conventional penetrating 
keratoplasty cannot be ascertained without long-term data. Comparative data concerning 
endothelial transplantation are also sparse. This evolving procedure is at a stage where case 
reports have given way to large series [41,42]. Two observations from these series give some 
cause for concern. Firstly, the visual results may be less than expected. In a large series in 
which the relationship between post-transplantation corneal thickness and acuity was 
measured in eyes chosen because they did not have macular disease, the visual acuities 
reported were not particularly impressive [41]. How they compare with the acuities achieved 
in patients receiving penetrating grafts remains to be determined. Another matter for concern 
is the low endothelial cell counts in patients after endothelial transplants [42]. This may 
compromise the long-term outcomes of these grafts, but again this remains to be determined. 
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Conclusions 
New approaches to reducing the impact of corneal allograft rejection on corneal graft survival 
have focussed on topical rather than systemic therapies, and on component corneal 
transplantation. These are sensible strategies to minimise the side-effects of potentially 
harmful systemic treatments. Drugs and biologics targeting key pathways co-stimulation, 
apoptosis, neovascularization and lymphangiogenesis have attracted particular interest and 
have led to improved graft outcome in experimental animals. Developments in gene therapy 
of the cornea have included improved vector design, including cornea-specific promoters. The 
most successful strategies to reduce the incidence of experimental corneal graft rejection have 
been those in which more than one pathway has been targeted: it now seems likely that to 
improve allograft survival clinically, simultaneous modulation of multiple axes of the 
complex rejection process will be necessary. Randomised controlled clinical trials in clinical 
penetrating corneal transplantation are finally being reported, so that some high-level 
evidence to guide practice is becoming available. There is still a dearth of evidence on the 
long-term outcomes of the newer component corneal graft procedures. 
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Figure legend 
 
Figure 1 Potential sites of intervention in corneal allograft rejection 
 
a) Corneal allograft rejection may be prevented by local inhibition or activation of co-
stimulatory molecules of the B7 family, depending on their function. Alternatively, inhibition 
of T cells, by induction of apoptosis in T cells by FasL, calcineurin blockers or 
immunosuppressive cytokines may be used. Novel therapies have also focused on the corneal 
endothelium itself, by exposure to molecules that prevent endothelial cell apoptosis in 
response to damage.  
 
b) Corneal allograft rejection may also be prevented by inhibition of the systemic immune 
response to a graft. Approaches have included prevention of APC migration to draining 
lymph node, systemic inhibition of antigen presentation, or use of systemic 
immunosuppressive drugs. 
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